Style | Citing Format |
---|---|
MLA | Babaei Z, et al.. "Sar131675 Receptor Tyrosine Kinase Inhibitor Induces Apoptosis Through Bcl-2/Bax/Cyto C Mitochondrial Pathway in Human Umbilical Vein Endothelial Cells." Anti-Cancer Agents in Medicinal Chemistry, vol. 22, no. 5, 2022, pp. 943-950. |
APA | Babaei Z, Panjehpour M, Parsian H, Aghaei M (2022). Sar131675 Receptor Tyrosine Kinase Inhibitor Induces Apoptosis Through Bcl-2/Bax/Cyto C Mitochondrial Pathway in Human Umbilical Vein Endothelial Cells. Anti-Cancer Agents in Medicinal Chemistry, 22(5), 943-950. |
Chicago | Babaei Z, Panjehpour M, Parsian H, Aghaei M. "Sar131675 Receptor Tyrosine Kinase Inhibitor Induces Apoptosis Through Bcl-2/Bax/Cyto C Mitochondrial Pathway in Human Umbilical Vein Endothelial Cells." Anti-Cancer Agents in Medicinal Chemistry 22, no. 5 (2022): 943-950. |
Harvard | Babaei Z et al. (2022) 'Sar131675 Receptor Tyrosine Kinase Inhibitor Induces Apoptosis Through Bcl-2/Bax/Cyto C Mitochondrial Pathway in Human Umbilical Vein Endothelial Cells', Anti-Cancer Agents in Medicinal Chemistry, 22(5), pp. 943-950. |
Vancouver | Babaei Z, Panjehpour M, Parsian H, Aghaei M. Sar131675 Receptor Tyrosine Kinase Inhibitor Induces Apoptosis Through Bcl-2/Bax/Cyto C Mitochondrial Pathway in Human Umbilical Vein Endothelial Cells. Anti-Cancer Agents in Medicinal Chemistry. 2022;22(5):943-950. |
BibTex | @article{ author = {Babaei Z and Panjehpour M and Parsian H and Aghaei M}, title = {Sar131675 Receptor Tyrosine Kinase Inhibitor Induces Apoptosis Through Bcl-2/Bax/Cyto C Mitochondrial Pathway in Human Umbilical Vein Endothelial Cells}, journal = {Anti-Cancer Agents in Medicinal Chemistry}, volume = {22}, number = {5}, pages = {943-950}, year = {2022} } |
RIS | TY - JOUR AU - Babaei Z AU - Panjehpour M AU - Parsian H AU - Aghaei M TI - Sar131675 Receptor Tyrosine Kinase Inhibitor Induces Apoptosis Through Bcl-2/Bax/Cyto C Mitochondrial Pathway in Human Umbilical Vein Endothelial Cells JO - Anti-Cancer Agents in Medicinal Chemistry VL - 22 IS - 5 SP - 943 EP - 950 PY - 2022 ER - |